small molecule

FORZINITY

ELAMIPRETIDE HYDROCHLORIDE

Loss of exclusivityFebruary 2034latest FDA-listed patent expiry

CompanyStealth BioTherapeutics →View the full company profile on CliffBio

Drug detail

Brand name	FORZINITY
Active ingredient	ELAMIPRETIDE HYDROCHLORIDE
Strength	EQ 280MG BASE/3.5ML (EQ 80MG BASE/ML)
Dosage form	SOLUTION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	September 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12268724	February 2034	use U-4277
11771734	February 2034	use U-4277
11083772	February 2034	use U-4277
11083771	February 2034	use U-4277
9687519	February 2034	use U-4277
7576061	January 2027	substance, product

Regulatory exclusivity

Code	Expires
ODE-551	September 2032
NCE	September 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.